M2SR shows promise as a universal flu vaccine
At FluGen we’re dedicated to improving public health by developing a vaccine that can prevent disease caused by all forms of the deadly influenza virus. We are fighting a virus that mutates quickly and results in over 200,000 hospitalizations and up to 79,000 deaths in the U.S. alone. Worldwide, influenza causes 290,000 to 650,000 deaths every year. Based in Madison, Wisconsin, FluGen is developing M2SR, an influenza vaccine that is poised to enter human trials. We are committed to forging a new and more effective weapon in the fight against influenza.